Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine.
The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given after chemotherapy in patients with locally advanced bladder cancer.
This practice-changing study showed how the addition of immunotherapy can have a dramatic impact on the lives of patients with certain cancers.
Also recognized for 9 “Exemplars” for top performance Leaders and team members celebrate Inova Mount…
New Prince William County location offers medical oncology, hematology, breast surgery, infusion and Inova Peterson…
Kathleen Harden, MD is a breast oncology physician, board-certified in medical oncology and internal medicine…
Dru Smith, an interstitial lung disease patient, shares his experience and care journey. Reston resident…
Tuesday, Oct. 27 Leesburg, VA, — As part of the national Stop the Bleed® campaign,…
Hospital opened in 1976 as a 76-bed community hospital and has grown into a regional…